Vistagen Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Phone
650-577-3600
Fiscal Year End
0331
EIN
205093315
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Material Events
8-K
Strategy Change
March 11, 2026
High Impact
- Extended Cash Runway: Funding operations into 2027, easing immediate financial pressure.
- Sharpened Focus on Fasedienol: Prioritizing the lead drug candidate for acute social anxiety disorder.
8-K
Financial Distress
February 6, 2026
High Impact
- Vistagen is a clinical-stage biopharmaceutical company focused on treatments for anxiety, depression, and other CNS disorders.
- The company is actively exploring all options to regain Nasdaq compliance, including strategic financing or accelerating key clinical milestones.
8-K
Other
December 22, 2025
High Impact
- Vistagen Therapeutics' main anxiety drug, fasedienol, failed to meet its primary goal in the Phase 3 PALISADE-3 study for social anxiety disorder.
- Fasedienol did not show significant improvement in anxiety symptoms compared to a placebo.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.